In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising new and repurposed therapies for pulmonary fibrosis.

This year in type 1 diabetes, researchers advanced immune-reprogramming nanoparticle therapies and hypoimmune stem cell transplants, launched pivotal islet cell therapy trials, updated screening and treatment guidelines, and warned that cuts to research funding could slow future innovation.

Breakthrough treatments, shifting care models and persistent system challenges defined cancer care this year, from evidence that CAR T-cell therapy can lower costs and treatment burden in mantle cell lymphoma to promising off-the-shelf cancer vaccines.

This year, we explored how innovations in women's health are bridging care gaps, addressing biases and enhancing access to vital treatments and screenings.

Tylenol and autism, the Inflation Reduction Act, the One Big Beautiful Bill, Most Favored Nation pricing and direct drug sales to consumers were some of the biggest news items we covered in 2025.

Medicare price negotiations, higher costs driven by cancer and GLP-1 drugs and Medicare’s pilot program for obesity drugs are some of the biggest trends this year that will continue to impact managed care in 2026.

Transparency, prior authorization, PBM reform and PBM offered genomics testing are some the trends Formulary Watched tracked in 2025.

Discover groundbreaking treatments for prurigo nodularis, including vixarelimab and soficitinib, offering hope for effective symptom relief and improved quality of life.

The approval comes two months after Jascayd (nerandomilast) was approved for idiopathic pulmonary fibrosis.